A look in­to the 340B ex­plo­sion of growth as Gilead and J&J join more than a dozen peers set­ting their own terms

As a new re­port doc­u­ments the ex­plo­sive growth of a fed­er­al pro­gram pro­vid­ing dis­count­ed drugs for low-in­come Amer­i­cans, two more large phar­ma com­pa­nies — Gilead and John­son & John­son — will place new re­stric­tions around their poli­cies for the pro­gram, known as 340B.

In­clud­ing Gilead and J&J, a to­tal of 16 phar­ma com­pa­nies have now re­worked their 340B op­er­a­tions over the last sev­er­al years as law­suits have sought to con­strain the firms from what they see as a bal­loon­ing por­tion of the US pre­scrip­tion drug mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER